News

Recent Enlivex Findings Show Lasting Benefits in Knee Pain Relief

Recent Enlivex Findings Show Lasting Benefits in Knee Pain Relief

Encouraging Results from Enlivex Therapeutics Study

In recent findings, Enlivex Therapeutics Ltd. (NASDAQ: ENLV), a company focused on innovative macrophage reprogramming immunotherapy, released compelling data from their Allocetra™ trial aimed at treating moderate to severe knee osteoarthritis (OA). The six-month follow-up of their Phase IIa clinical trial has shown substantial progress and maintained impact, offering hope for patients dealing with this often debilitating condition.

Summary of Six-Month Findings

The results unveiled substantiate earlier observations from the study conducted over three months, showcasing the efficacy of Allocetra™ among older patients aged 60 and above. This comprehensive trial included multiple assessments of pain reduction and functional improvement.

Efficacy of Allocetra™

Data collected indicates a consistent and meaningful decrease in pain scores and improvement in joint function. Notably, at the three-month mark, patients treated with Allocetra™ experienced a significant reduction in pain by -26.8 points compared to a -13.4 points drop for those receiving placebo, translating to a 99% improvement. As the trial progressed to the six-month evaluation, patients continued to report a reduction of -27.8 points in the Allocetra™ group, reflecting an 80% improvement compared to placebo treated patients.

Safety Profile

Across the six-month period, Allocetra™ has exhibited a favorable safety profile, aligning with previously reported data from the three-month follow-up, thereby reinforcing its potential as a safe treatment option for knee OA.

Expert Perspectives

Professor Philip Conaghan, an authority on osteoarthritis, remarked on the increasing prevalence and consequences of knee OA due to aging and obesity. His insights emphasize the pressing demand for effective treatments. He stated, "With inflammatory mediators playing a central role in the progression of knee pain, the promising results of Allocetra™ present an innovative treatment pathway that deserves attention."

Oren Hershkovitz, Ph.D., the CEO of Enlivex, conveyed optimism about the trial's results, stating, “The strength of the six-month outcomes outlines the sustained relief that Allocetra™ offers, portraying it as a transformative option for individuals suffering from age-related primary knee OA.”

Future Developments

As the study moves forward, Einat Galamidi, M.D., Chief Medical Officer of Enlivex, has expressed enthusiasm for the upcoming Phase IIb trial. This will aim to further explore the benefits of Allocetra™ in treating knee osteoarthritis, with plans to initiate the trial in the first half of the upcoming year.

Understanding Knee Osteoarthritis

Osteoarthritis remains the most prevalent form of arthritis, impacting millions globally. As projected, it's anticipated that numerous individuals will suffer from this condition by the next few decades, indicating an urgent need for effective medical interventions. Knee osteoarthritis, in particular, is a major contributor to healthcare burdens, including surgeries and hospitalizations.

About Enlivex Therapeutics

Enlivex stands at the forefront of developing innovative therapies through the reprogramming of macrophages, aiming to improve immune response to life-threatening conditions. The company’s commitment to exploring new treatment avenues is reflected in its dedication to the ongoing study of Allocetra™, offering hope for enhanced quality of life for countless patients battling knee osteoarthritis.

Frequently Asked Questions

What is Allocetra™?

Allocetra™ is a cell therapy developed by Enlivex Therapeutics designed to reprogram macrophages, aiming to restore their homeostatic function.

What were the main findings of the six-month trial?

The trial demonstrated significant and durable pain reduction alongside improved joint function among patients treated with Allocetra™ compared to placebo.

What is the importance of the age group selected for the trial?

The elderly population, particularly those aged 60 and above, are more prone to the debilitating effects of knee osteoarthritis, making them a key demographic in treatment studies.

When is the next phase of the trial expected to start?

The Phase IIb trial is anticipated to commence in the first half of the upcoming year, further investigating the efficacy of Allocetra™.

Why is knee osteoarthritis a critical health issue?

Knee osteoarthritis is widespread, causing significant pain and impairment, leading to considerable healthcare costs and impacting quality of life for millions.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 312

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 350

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 303

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 330

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 638

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 342

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 479

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
PettiChat’s Digital Pet Twin Has Real Consumer Pull

Updated Category News Views 389

A Collar Gadget Is Chasing the Empty-House Problem Leave a dog or cat alone for a few hours and plenty of owners turn into amateur detectives. Did the cat eat? Has the dog been pacing? Why was that one weird noise caught on the home camera? Seattle startup PettiChat is trying to turn that itch into a product category with PettiLive!, a screen-based version of a pet that...

Continue Reading
FASTEN Data Offers an Early Look at Ladera Closure

Updated Category News Views 122

Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...

Continue Reading
DataBeyond Puts AI Sorting Before a Waste Mountain

Updated Category News Views 182

Trash is a lousy place to look for technological glamour, which is precisely why DataBeyond's COP31 appearance deserves a sober look. On November 19 in Antalya, Türkiye, the Hangzhou-based equipment provider used a China Pavilion event to lay out its case for AI, optical sensing and robots in resource recovery. That is not a magic-green headline. It is a practical...

Continue Reading

Top 5 Most Recently Viewed Articles

HALiXPEDITE Revolutionizes Biologics Therapy Development Process

Updated Category News Views 147

HALiXPEDITE: Transforming the Future of Biologics Development HALIX, a prominent global healthcare Contract Development and Manufacturing Organization (CDMO), recently unveiled its innovative platform, HALiXPEDITE, at a notable conference. This platform is specifically designed to expedite the development of biologics therapies, focusing on a streamlined approach to...

Continue Reading
Day One Biopharmaceuticals to Share Q3 2025 Insights

Updated Category News Views 170

Day One Biopharmaceuticals to Present Q3 2025 Financial Results In a busy season for the biopharmaceutical industry, Day One Biopharmaceuticals (Nasdaq: DAWN) has announced it will host a live conference call and webcast aimed at reporting its financial results and outlining corporate progress for the third quarter of 2025. Conference Call Details The event is scheduled...

Continue Reading
Leica Biosystems Promotes DICOM Standards for Digital Pathology

Updated Category News Views 114

Leica Biosystems Promotes DICOM Standards for Digital Pathology Leica Biosystems, a prominent figure in anatomic pathology, has recently made waves in the medical field with a bold new initiative. By announcing the non-enforcement of their Digital Pathology DICOM (Digital Imaging and Communications in Medicine) patent portfolio, they aim to boost the implementation of...

Continue Reading
LYNPARZA: A Breakthrough in Early Breast Cancer Treatments

Updated Category News Views 288

Significant Survival Benefits with LYNPARZA in Breast Cancer Recent findings from the OlympiA Phase III trial bring exciting news for patients battling early breast cancer. AstraZeneca and Merck & Co., Inc.'s LYNPARZA (olaparib) has showcased profound improvements in survival rates among patients with germline BRCA-mutated HER2-negative high-risk early breast cancer. This...

Continue Reading
EuroDry Limited's Stock Experiences Volatility Amid Challenges

Updated Category News Views 229

EuroDry Limited Faces Stock Turmoil EuroDry Ltd. (NASDAQ: EDRY), a leading provider in drybulk shipping, has recently encountered a tumultuous phase, with its stock reaching a noteworthy low at $14.1. This decline marks a significant reflection on the year's challenges the company has faced, indicated by a -14.71% change over the past year. Market Conditions and...

Continue Reading